EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

N 6 ‐methyladenosine‐modified FAM111A‐DT promotes hepatocellular carcinoma growth via epigenetically activating FAM111A

Jian Pu, Zuoming Xu, Youguan Huang, Jiahui Nian, Meng Yang, Quan Fang, Qing Wei, Zihua Huang, Guoman Liu, Jianchu Wang, Xianjian Wu, Huamei Wei iD

Cancer Science · 2023-09 · 114 (9) · 3649-3665

DOI: 10.1111/cas.15886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 03.07.2023. Verfasst von Jian Pu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangxi Natural Science Foundation Project, Guangxi Science and Technology plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As an epitranscriptomic modulation manner, N 6 ‐methyladenosine (m 6 A) modification plays important roles in various diseases, including hepatocellular carcinoma (HCC). m 6 A modification affects the fate of RNAs. The potential contributions of m 6 A to the functions of RNA still need further investigation. In this study, we identified long noncoding RNA FAM111A‐DT as an m 6 A‐modified RNA and confirmed three m 6 A sites on FAM111A‐DT. The m 6 A modification level of FAM111A‐DT was increased in HCC tissues and cell lines, and increased m 6 A level was correlated with poor survival of HCC patients. m 6 A modification increased the stability of FAM111A‐DT transcript, whose expression level showed similar clinical relevance to that of the m 6 A level of FAM111A‐DT. Functional assays found that only m 6 A‐modified FAM111A‐DT promoted HCC cellular proliferation, DNA replication, and HCC tumor growth. Mutation of m 6 A sites on FAM111A‐DT abolished the roles of FAM111A‐DT. Mechanistic investigations found that m 6 A‐modified FAM111A‐DT bound to FAM111A promoter and also interacted with m 6 A reader YTHDC1, which further bound and recruited histone demethylase KDM3B to FAM111A promoter, leading to the reduction of the repressive histone mark H3K9me2 and transcriptional activation of FAM111A . The expression of FAM111A was positively correlated with the m 6 A level of FAM111A‐DT, and the expression of methyltransferase complex, YTHDC1, and KDM3B in HCC tissues. Depletion of FAM111A largely attenuated the roles of m 6 A‐modified FAM111A‐DT in HCC. In summary, the m 6 A‐modified FAM111A‐DT/YTHDC1/KDM3B/FAM111A regulatory axis promoted HCC growth and represented a candidate therapeutic target for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsRNA, Long NoncodingHumansCell Line, TumorTranscriptional ActivationCell ProliferationRNAGene Expression Regulation, NeoplasticJumonji Domain-Containing Histone DemethylasesReceptors, Virus

Stichwörter der Autor:innen

DNA replicationN6-methyladenosineepigenetic modulationhepatocellular carcinomahistone methylation

Substanzen

RNARNA, Long NoncodingKDM3B protein, humanJumonji Domain-Containing Histone DemethylasesFAM111A protein, humanReceptors, Virus

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
  • Graduate College of Youjiang Medical University for Nationalities, Baise, China.
  • Department of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.

ORCID-Profile: Huamei Wei

Förderung

  • Guangxi Natural Science Foundation Project
  • Guangxi Science and Technology plan Project

Zitieren

APA

Pu, J., Xu, Z., Huang, Y., Nian, J., Yang, M., Fang, Q., Wei, Q., Huang, Z., Liu, G., Wang, J., Wu, X., & Wei, H. (2023). N 6 ‐methyladenosine‐modified FAM111A‐DT promotes hepatocellular carcinoma growth via epigenetically activating FAM111A. Cancer Science, 114(9), 3649-3665. https://doi.org/10.1111/cas.15886

Vancouver

Pu J, Xu Z, Huang Y, Nian J, Yang M, Fang Q, et al. N 6 ‐methyladenosine‐modified FAM111A‐DT promotes hepatocellular carcinoma growth via epigenetically activating FAM111A. Cancer Science. 2023;114(9):3649-3665. doi:10.1111/cas.15886

BibTeX
@article{Pu2023,
  author = {Pu, Jian and Xu, Zuoming and Huang, Youguan and Nian, Jiahui and Yang, Meng and Fang, Quan and Wei, Qing and Huang, Zihua and Liu, Guoman and Wang, Jianchu and Wu, Xianjian and Wei, Huamei},
  title = {N 6 ‐methyladenosine‐modified FAM111A‐DT promotes hepatocellular carcinoma growth via epigenetically activating FAM111A},
  journal = {Cancer Science},
  year = {2023},
  volume = {114},
  number = {9},
  pages = {3649--3665},
  doi = {10.1111/cas.15886}
}
Kostenlos starten →